OATD-01 is under clinical development by Molecure and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OATD-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OATD-01 overview

GLPG-4716 is under development for the treatment of asthma, sarcoidosis and interstitial lung diseases/idiopathic pulmonary fibrosis. The drug candidate is administered through oral route. The drug candidate acts by targeting acidic mammalian chitinase (AMCase) and chitotriosidase-1 (CHIT1). It was also under development for the treatment of inflammatory bowel disease.

Molecure overview

Molecure is a clinical-stage biopharmaceutical company. It carries out the discovery, development and commercialization of therapeutics for cancer and respiratory diseases. The company’s lead clinical candidate OATD-01 is an inhibitor of chitinases that are being developed to treat multiple lung diseases including idiopathic pulmonary fibrosis, asthma and sarcoidosis. It is also developing CHIT-1 and YKL-40 for glioblastoma multiforme (GBM) and other cancers. The company works in collaboration with academics, research institutions and contract research organizations for drug discovery and development. Molecure is headquartered in Warsaw, Masovia, Poland.

For a complete picture of OATD-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.